1. Svatek RS et al (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66(2):253–262
2. Babjuk M, Burger M, Compérat E, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, D.C. Guidelines Associates, Capoun O, Dominguez Escrig JL, Hernandez V, Peyronnet B, Seisen T, Soukup V (2019) EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS).
https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
. Zugegriffen: 1. April 2019
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2016) S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1. AWMF-Registrierungsnummer 032/038OL
4. Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–465 (discussion 475–7)
5. Fernandez-Gomez J et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5):2195–2203